Daiichi Sankyo adds a cancer target to ArQule pact; BrainStorm gets green light for stem cell trial;

 @FierceBiotech: Jazz shares hit sour note as FDA rejects fibromyalgia drug. Article | Follow @FierceBiotech

 @JohnCFierce: Once heard Peter Drucker talk about U.S. tech revolutions. 1st years: Disaster, as everyone piles into the hype. 2nd 10 years: Revolution. | Follow @JohnCFierce

> Daiichi Sankyo must like what it's seen so far in its discovery pact with ArQule. The Japanese company has added a third cancer target to their agreement with an option on a fourth. Story

> BrainStorm Cell Therapeutics has been cleared to launch clinical trials of its stem cell therapy for ALS in Israel. The therapy for Lou Gehrig's disease uses stem cells extracted from bone marrow. Report

> Germany's Noxxon Pharma says it brought its Series D total up to €35 million. Noxxon release

> Albireo is touting what it calls positive top-line results from a Phase IIb study in chronic idiopathic constipation assessing the efficacy and safety of three different dose levels of A3309 during an eight-week trial. Albireo release

And Finally... Scripps Research Institute scientists say they have shown for the first time that the neurotransmitter serotonin uses a specialized signaling pathway distinct from the pathways used by hallucinogenic substances. That insight could have a "profound effect on the development of new therapies for a number of disorders, including schizophrenia and depression. Release